| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2013: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2012: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Research Abstract |
The aim of this study is to develop amyloid imaging using 19F MRI. We have developed a novel 19F-containing curcumin derivative (named FMeC1 or Shiga-Y5) as a potential 19F MRI probe for amyloid imaging. When Tg2576 mice, a transgenic mouse model of Alzheimer's disease, at 20-22 months of age were peripherally injected with FMeC1, dose-dependent increasing in the level of 19F signal was observed in 19F MR spectra obtained from the whole head. 19F MR image showed remarkable levels of 19F signal in the brain of Tg2576 mice after the injection of FMeC1 at a dose of 200 mg/kg. There are no significant 19F signals in the brain of FMeC1-injected wild-type mice. Histological analysis of FMeC1-injected Tg2576 mouse brain showed strong fluorescence signal for FMeC1, and most of this signal was co-localized with beta-amyloid peptide-immunoreactivity. These results suggest the potential benefit of 19F MRI with FMeC1 for amyloid imaging.
|
